Fortitude Family Office’s Eledon Pharmaceuticals ELDN Stock Holding History

Fortitude Family Office’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232	Buy	+59	New	+$215	﹤0.01%	2096

Other funds holding ELDN

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Howard Financial Services Dallas, Texas $1B AUM 20.02% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return

Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Fortitude Family Office's ELDN Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 59 shares worth $232. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings.

28 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Fortitude Family Office held 59 shares of Eledon Pharmaceuticals worth $232 as of Q2 2026.
Eledon Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2096 holding.
28 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.